For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Private Banking & Wealth Management
Professional Solutions
Investment Management
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Private Banking
Investment management
Investment banking
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37
Belgium
+32 (0)32 86 69 80
Switzerland
+41 (0)43 377 11 11
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00
United Kingdom
+44 (0)20 36 36 94 00
France
+33 (0)18 375 62 73
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00
United Kingdom
+44 (0)20 36 36 94 00
United States of America
+1 (0)21 237 601 34
Mainstay
Mainstay Medical is an Irish medical technology company aiming to treat chronic low back pain by using their active implantable device ReActiv8
- Mainstay Medical floated on Euronext Paris and the Enterprise Securities Market of the Irish Stock Exchange
- Proceeds of the IPO will be used to conduct clinical trials and to obtain CE mark approval
- Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner and placed 41.6% of the shares with US investors